Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2010

View Archived Issues

Kalypsys claims new GPR119 receptor agonists

Pulmagen Therapeutics discovers new inhibitors of neutrophil elastase

Boehringer Ingelheim discovers novel chymase inhibitors

Phosphoprofiling approach identifies drug-specific biomarkers of PI3K pathway inhibition

Meta-analysis reveals potential link between ARBs and onset of cancer

GCC-2680 shows promise as obesity therapeutic based on preclinical data

Amsterdam Molecular Therapeutics provides update on Glybera MAA

Anchor Therapeutics secures funds to advance pepducin drug candidates

Bioniche provides development update on Urocidin in bladder cancer

Bolder BioTech receives grant to study IL-11 analogue for acute radiation syndrome

Protalex treats first patient in phase Ib PRTX-100 trial in RA

SkyePharma regains U.S. rights to Flutiform for asthma

ADDF funds Cognition Therapeutics to advance AD candidate

ISCO provides update on stem cell-based eye care programs

Scientists link clozapine-induced myocarditis to obesity, creatinine kinase and C-reactive protein

FDA extends review of Acetadote sNDA for non-acetaminophen acute liver failure

EpiCept receives refusal to file letter from FDA for Ceplene NDA

Scientists identify new pathway of tricarboxylic acid metabolism in P. falciparum

Precedex IV 200 mcg approved for long-term use in Japan

New DGAT-1 inhibitors claimed by Banyu Pharmaceutical

Pfizer discloses new inhibitors of DGAT-1

FDA advisory committee votes against use of JZP-6 for fibromyalgia

FDA continues safety review of Stalevo and possible increased cardiovascular risk

University of Pittsburgh receives donation for stem cell research on corneal scarring

GSK begins phase III trials of herpes zoster vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...